.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,622,985

« Back to Dashboard

Claims for Patent: 5,622,985

Title: Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
Abstract:A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.
Inventor(s): Olukotun; Adeove Y. (Hopewell, NJ), Alexander; John C. (Winnetka, IL)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:08/424,984
Patent Claims: 1. A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.

2. The method as defined in claim 1 wherein said inhibitor of the enzyme HMG CoA reductase is mevastatin, lovastatin, pravastatin or velostatin.

3. The method as defined in claim 1 wherein said inhibitor of the enzyme HMG CoA reductase is a pyrazole analog of a mevalonolactone, an indene analog of mevalonolactone, a 3-carboxy-2-hydroxypropane-phosphinic acid derivative, a 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-one, an imidazole analog of mevalonolactone, a naphthyl analog of mevalonolactone, an octahydro-naphthalene, fluindostatin, a keto analog of lovastatin or a 2,3-di-substituted pyrrole, furan or thiophene.

4. The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is pravastatin.

5. The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is administered in single or divided doses of from about 0.5 to about 100 mg/one to four times daily.

6. The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is administered in single or divided doses of from about 5 to about 80 mg/one to four times daily.

7. A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an HMG CoA reductase inhibitor in combination with a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor.

8. The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is captopril or fosinopril.

9. The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor includes a mercapto moiety and is a substituted proline derivative.

10. The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is captopril, zofenopril, enalapril, ceranopril, fosinopril, lisinopril or fentiapril.

11. The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is a phosphonate substituted amino or imino acid or salt thereof, a mercaptoacyl derivative of a substituted proline, a carboxyalkyl dipeptide, a phosphinylalkanoyl proline or a phosphonoamidate.

12. The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is present in a weight ratio to the ACE inhibitor of within the range of from about 0.001:1 to about 1000:1.

13. The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is pravastatin.

14. The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 0.1 to about 500 mg/one to four times daily.

15. The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is pravastatin and the ACE inhibitor is captopril, fosinopril or ceranopril.

16. The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 2 to about 50 mg/one to four times daily.

17. The method as defined in claim 7 wherein the mammalian species treated is normotensive.

18. The method as defined in claim 17 wherein the ACE inhibitor is administered in an amount below that required to cause hemodynamic effects.

19. The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is employed in an amount of within the range of from about 5 to about 80 mg and the ACE inhibitor is employed in an amount within the range of from about 2 to about 5 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc